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This study aims to establish the corneal nerve fiber (CNF) morphological alterations in a large cohort of type 2 diabetic patients
and to investigate the association between the bead size, a novel parameter representing composite of accumulated mitochondria,
glycogenparticles, and vesicles inCNF, and the neurophysiological dysfunctions of the peripheral nerves. 162 type 2 diabetic patients
and 45 healthy control subjects were studied in detail with a battery of clinical and neurological examinations and corneal confocal
microscopy. Compared with controls, patients had abnormal CNF parameters. In particular the patients had reduced density and
length of CNF and beading frequency and increased bead size. Alterations in CNF parameters were significant even in patients
without neuropathy. The HbA1c levels were tightly associated with the bead size, which was inversely related to the motor and
sensory nerve conduction velocity (NCV) and to the distal latency period of the median nerve positively. The CNF density and
length positively correlated with the NCV and amplitude. The hyperglycemia-induced expansion of beads in CNF might be a
predictor of slow NCV in peripheral nerves in type 2 diabetic patients.
1. Introduction
Diabetic neuropathy is a major complication of diabetes that
may affect the sensory, autonomic, and motor nerves [1].
Mitochondria play a pivotal role in controlling nerve function
by their fusion, fission, and trafficking [2, 3] and their
morphological and functional anomalies play a pivotal role
in developing diabetic neuropathy [4, 5]. Corneal confocal
microscopy (CCM) has been used to diagnose small C-fiber
neuropathy [6, 7] and visualizes composites of the accumu-
lated mitochondria, glycogen particles, and vesicles [8] as
a bead [9]. In diabetic mice the presence of collections of
small mitochondria and the formation of markedly enlarged
mitochondria has been reported by Schmidt et al. [10]. Using
IENFs of patients with diabetic neuropathy, Hamid et al. [4]
observed larger mitochondrial signals composed of clustered
smaller, potentially dysfunctional mitochondria or of larger
predegenerative mitochondria due to a disruption in axonal
transport. In small fiber neuropathy patients with relatively
preserved IENFs, mitochondrial loss as judged by the signif-
icant reduction of mitochondrial oxidative phosphorylation
was found [11]. However, there has been no report to associate
the bead size (BS) of corneal nerve fibers (CNFs) and
dysfunctions of the peripheral nerves in diabetic patients,
because the size of an individual bead is too small to be
assessed. We already reported that enlarging and smoothing
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of beads by S-Spline Max algorithm make it feasible to
determine the size of an individual bead [12].
The aim of the present study is to associate the BS in
CNFs determined by subsequent image processing with the
neurophysiological dysfunctions of the peripheral nerves in
patients with type 2 diabetes, elucidating whether the BS of
CNFs might predict dysfunctions in the peripheral nerves.
2. Research Design and Methods
2.1. Subjects. 162 Japanese patients with type 2 diabetes and
45 healthy control subjects (HbA1c < 5.7% (38.8mmol/mol),
fasting plasma glucose < 5.5mmol/L or casual postprandial
plasma glucose < 7.7mmol/L) were enrolled in this study
at the period between May 2013 and January 2015 at the
Ishibashi Clinic, Hiroshima, Japan. Subjects were excluded
from the study if they consumed alcohol > one unit/day, had
neurological symptoms due to neurological disorders other
than diabetic neuropathy or had been diagnosed with the
neuropathy due to another cause, or wore contact lenses or
had history of refractive surgery or anterior segment trauma.
The healthy volunteers were recruited from the general pop-
ulation. Written informed consent was obtained according
to the Declaration of Helsinki. The Ethics Committee of
the Ishibashi Clinic approved the protocol of the present
research.
2.2. Laboratory Data. The HbA1c levels were converted
to National Glycohemoglobin Standardization Program
(NGSP) units by adding 0.4% to the measured values [13]
and subsequently converted to the International Federa-
tion of Clinical Chemistry values by using the equation
[(10.93NGSP)−23.50].The serum creatinine, lipid levels, the
urinary albumin/creatinine ratio (ACR), and the estimated
glomerular filtration rate (eGFR) were also determined.
2.3. Neurophysiological Examinations. Electrophysiology
and nerve conduction velocity (NCV) studies were per-
formed using an electromyography instrument (NeuroPak
S1, NIHONKOHDEN, Tokyo, Japan).Themotor conduction
velocity (MCV, median nerve) and sensory conduction
velocity (SCV, ulnar and sural nerve), action potential
amplitudes of these three nerves, and the distal latency period
of the median nerve in the wrist segment were determined.
The vibration perception threshold (VPT) was measured
at the left medial malleolus using a biothesiometer (Biomed-
ical Instruments, Newbury, OH, USA). The average of eight
readings has been included. The warm and cold perception
thresholds (PTs) at the dorsum of the foot were determined
using a thermal stimulator that was controlled by a Peltier
element (Intercross-200, Intercross Co., Tokyo, Japan). To
assess the cardiovagal function of the autonomic nervous
system, the coefficient of variation of R-R intervals (CVR-R)
was calculated from the R-R intervals of 200 samples on an
electrocardiogram.
2.4. Assessment of Neuropathy. Severity of neuropathy and
neurological deficits were assessed using the Neuropathy
Disability Score (NDS) [14] which includes evaluation of
vibration, pin prick, and temperature perception aswell as the
presence or absence of ankle reflexes to establish the severity
of neuropathy: NDS 0–2, no neuropathy; NDS 3–5, mild
neuropathy; NDS 6–8, moderate neuropathy; and NDS 9-10,
severe neuropathy.
2.5. CCM. All study subjects were examined using Heidel-
berg Retina Tomograph (HRT III, Heidelberg Engineering,
Heidelberg, Germany) [9]. The technicians who were per-
forming CCM examination were blinded to patient groups
and the signs and symptoms of patients. The examined eye
was anesthetized by instilling one drop of 0.4% benoxinate
hydrochloride (Santen Pharmaceutical Co., Osaka, Japan).
Comfort Gel (Dr. Mann Pharma, Berlin, Germany) was
applied to the lens, and a disposable sterilized TomoCap
(Heidelberg Engineering GmbH, Dossenheim, Germany)
was mounted on the holder to cover the objective lens. After
applying Comfort Gel to the TomoCap, the lens was slowly
advanced until the gel touched the cornea. More than 50
images of the subbasal nerve plexus were captured using a
section mode, and we analyzed at least 6 high-clarity images
per subject for the quantification of the following parameters
to define changes in the CNFs: (1) CNF density (CNFD):
the total number of major nerve fibers/mm2 of corneal
tissue; (2) CNF length (CNFL): the total length of all nerve
fibers (mm/mm2); (3) corneal nerve branch density (CNBD):
the number of branches emanating from all major nerve
trunks/mm2 of corneal tissue; (4) tortuosity grade (TG); (5)
frequency/0.1mm of beading (BF); and (6) BS determined
after enlarging 5 times and smoothing the original image
of CCM using S-Spline Max algorithm (PhotoZoom Pro 4,
Gungle Inc., Tokyo, Japan). The pixel numbers of 120 beads
were counted using Photoshop Elements 8.0 (Adobe Systems
Inc., San Jose, CA, USA) and averaged.
Except for the TG and BS, all measurements were per-
formed using ImageJ (Texelcraft, Tokyo, Japan); the TG was
measured by the grading system of Oliveira-Soto and Efron
[15].
2.6. Statistical Analyses. The post hoc analysis of sample
power revealed that, with the use of a one-sided ANOVA
(significance of 0.05) and Kruskal-Wallis test, the present
study population provided statistical power ranged from 0.82
to 0.99. All statistical analyses were performed using the
SPSS medical package (SPSS version 19, Chicago, IL, USA).
All values are presented as the mean ± SEM. All data sets
were tested for the normality using the Shapiro-Wilk test.
For normally distributed variables, the comparisons between
controls and total diabetic patients or subgroups stratified
by NDS were made using one-way ANOVA (for continuous
variables) and the 𝜒2-test (for categorical variables) followed
by Bonferroni corrections. For nonnormally distributed vari-
ables, the Kruskal-Wallis test was applied with subsequent
Mann-Whitney 𝑈 test and Bonferroni corrections. The cor-
relations between the CNF measures and the clinical factors
or the results of neurophysiological tests were assessed by the
Spearman rank correlation test.The sensitivity and specificity
of CCMmeasures in differentiating between control subjects
and patients without neuropathy or between patients without
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Table 1: Clinical characteristics and neurophysiological test of the control subjects, type 2 diabetic patients, and their subgroups stratified by
the stages of neuropathy.
Control
subjects
Type 2 diabetic patients
All type 2
diabetic
patients
Stages of neuropathy
No
neuropathy
NDS (0–2)
Mild
NDS (3–5)
Moderate
NDS (6–8)
Severe
NDS (9-10)
Number (M/F) (%) 45 (27/18)(60/40)
162 (106/56)
(65.4/34.6)
47 (29/18)
(61.7/38.3)
56 (37/19)
(66.1/33.9)
46 (31/15)
(67.4/32.6)
13 (9/4)
(69.2/30.8)
Age (years) 52.8 ± 0.7 53.1 ± 0.8 52.4 ± 1.4 52.0 ± 1.4 54.2 ± 1.4 56.9 ± 2.5
Duration of diabetes (years) 6.7 ± 0.5 5.0 ± 0.8 6.4 ± 0.7 8.1 ± 1.1 9.2 ± 1.4
BMI (kg/m2) 23.2 ± 0.6 25.2 ± 0.3∗ 25.2 ± 0.6 25.2 ± 0.5† 25.1 ± 0.7 25.8 ± 1.2
SBP (mmHg) 134.4 ± 2.2 153.0 ± 1.8∗ 149.9 ± 3.3∗ 152.3 ± 2.8∗ 155.7 ± 3.9∗ 158.5 ± 7.8‡
DBP (mmHg) 79.8 ± 0.9 90.4 ± 0.9∗ 90.6 ± 1.7∗ 90.3 ± 1.4∗ 90.5 ± 1.6∗ 90.1 ± 3.0†
Number treated with ARB/ACEI (%) 2 (4.4) 26 (16.0)† 8 (17.0) 7 (12.5) 10 (21.7)† 1 (7.7)
HbA1c (NGSP, %) 5.5 ± 0.04 8.7 ± 0.20∗ 8.5 ± 0.34∗ 9.0 ± 0.32∗ 8.4 ± 0.27∗ 9.8 ± 0.64∗
HbA1c (mmol/mol) 36.5 ± 0.41 69.4 ± 1.80 67.1 ± 3.48 72.0 ± 3.29 65.8 ± 2.81 79.6 ± 6.51
LDL-C (mmol/L) 3.16 ± 0.11 3.58 ± 0.08‡ 3.54 ± 0.16 3.79 ± 0.13† 3.34 ± 0.14 3.69 ± 0.31
Number treated with statins (%) 2 (4.4) 31 (19.1)† 10 (21.3) 11 (19.6) 8 (17.4) 2 (15.4)
HDL-C (mmol/L) 1.77 ± 0.072 1.47 ± 0.059∗ 1.38 ± 0.056∗ 1.59 ± 0.156 1.43 ± 0.064‡ 1.45 ± 0.096
Triglycerides (mmol/L) 1.45 ± 0.15 2.26 ± 0.12∗ 2.19 ± 0.24 2.34 ± 0.19‡ 2.27 ± 0.23† 2.20 ± 0.36
ACR (mg/gCr) 8.0 ± 1.6 99.8 ± 35.2∗ 58.9 ± 23.1‡ 49.6 ± 15.2∗ 176.5±118.4∗ 192.5 ± 78.9∗
eGFR (mL/min) 80.8 ± 2.3 83.5 ± 1.4 84.3 ± 2.7 85.4 ± 2.2 82.3 ± 2.7 77.3 ± 4.6
Mean NDS value 0 4.36 ± 0.22∗ 0.87 ± 0.12∗ 4.16 ± 0.10∗,§ 6.76 ± 0.12∗, 9.38 ± 0.14∗,¶
Neurophysiological test
MCV of MN (m/sec) 57.9 ± 0.44 53.7 ± 0.36∗ 54.8 ± 0.70‡ 53.6 ± 0.62∗ 52.4 ± 0.62∗ 48.2 ± 1.10∗,§,,#
Amplitude of MN (mV) 7.77 ± 0.37 6.00 ± 0.16∗ 6.90 ± 0.26 6.16 ± 0.28† 5.31±0.28∗,∗∗ 4.92 ± 0.81∗,∗∗
Distal latency of MN (msec) 3.16 ± 0.06 3.69 ± 0.053∗ 3.54 ± 0.11 3.71 ± 0.09∗ 3.79 ± 0.095∗ 3.79 ± 0.14‡
SCV of ulnar nerve (m/sec) 64.0 ± 0.62 59.5 ± 0.37∗ 61.2 ± 0.57 60.0 ± 0.58∗ 58.4 ± 0.73∗,†† 55.8 ± 1.40∗,∗∗,‡‡
Amplitude of ulnar nerve (𝜇V) 29.5 ± 2.3 19.6 ± 0.92∗ 22.7 ± 2.0 21.7 ± 1.5 16.0 ± 1.3∗ 12.2 ± 1.8∗,††
SCV of sural nerve (m/sec) 48.2 ± 0.39 45.7 ± 0.21∗ 47.1 ± 0.33 45.7 ± 0.34∗ 45.0±0.42∗,∗∗ 43.2 ± 0.55∗,§,‡‡
Amplitude of sural nerve (𝜇V) 12.5 ± 0.76 10.8 ± 0.58∗ 10.6 ± 0.42 10.3 ± 0.29 9.2 ± 0.34∗ 8.8 ± 0.70‡
Vibration PT (𝜇/120 c/s) 2.00 ± 0.29 3.61 ± 0.25∗ 2.48 ± 0.26 3.21 ± 0.32 3.88 ± 0.55‡ 8.48 ± 0.99∗,§,,¶
CVR-R (%) 3.71 ± 0.15 3.38 ± 0.12∗ 3.69 ± 0.24 3.54 ± 0.22 2.99 ± 0.18† 2.91 ± 0.40
Warm PT (W/m2) −554 ± 16.4 −628 ± 20.5‡ −545 ± 22.0 −612 ± 31.0 −652 ± 27.2† −915 ± 160∗,§
Cold PT (W/m2) 487 ± 16.5 573 ± 14.3∗ 520 ± 19.2 565 ± 17.0 585 ± 19.2†,∗∗ 769 ± 119∗,§
Data are the mean ± standard error of the mean in control subjects, type 2 diabetic patients, and their subgroups stratified by the stages of the neuropathy
according to the Neuropathy Disability Score (NDS) [14]. ∗𝑝 < 0.001 compared with control subjects, †𝑝 < 0.05 compared with control subjects, ‡𝑝 < 0.01
compared with control subjects, §𝑝 < 0.001 compared with patients without neuropathy, 𝑝 < 0.001 compared with patients withmild neuropathy, ¶𝑝 < 0.001
compared with patients with moderate neuropathy, #𝑝 < 0.05 compared with patients with moderate neuropathy, ∗∗𝑝 < 0.01 compared with patients without
neuropathy, ††𝑝 < 0.05 compared with patients without neuropathy, and ‡‡𝑝 < 0.05 compared with patients with mild neuropathy.
ACEI, angiotensin-converting enzyme inhibitor; ACR, albumin/creatinine ratio; ARB, angiotensin receptor blocker; BMI, body mass index; DBP, diastolic
blood pressure; eGFR, estimated glomerular filtration rate; HDL-C, high density lipoprotein-cholesterol; LDL-C, low density lipoprotein-cholesterol; MN,
median nerve; PT, perception threshold; SBP, systolic blood pressure.
neuropathy andwith neuropathywere assessed using receiver
operating characteristic (ROC) analysis. 𝑝 < 0.05 was
considered significant.
3. Results
3.1. Characteristics of Healthy Controls and Patients with
Type 2 Diabetes. The clinical characteristics and detailed
assessment of diabetic neuropathy in diabetic patients and
controls are summarized in Table 1. The gender ratio and
age were similar between controls, total diabetic patients,
and their subgroups. The BMI of all patients and the mild
neuropathy subgroup was higher than that in controls. The
blood pressure in all patients was higher than that in control
subjects. The angiotensin receptor blocker or angiotensin-
converting enzyme inhibitor was prescribed more frequently
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Table 2: Summary of corneal nerves morphological parameters in control subjects, type 2 diabetic patients, and their subgroups stratified by
the stages of neuropathy.
Corneal nerves morphological parameters Control
subjects
Patients with type 2 diabetes
All type 2
diabetic
patients
Stratified by stages of neuropathy
No
neuropathy
NDS (0–2)
Mild
NDS (3–5)
Moderate
NDS (6–8)
Severe
NDS (9-10)
Corneal nerve fiber density (CNFD) (no/mm2) 33.0 ± 1.2 23.3 ± 0.41∗ 25.3 ± 0.72∗ 23.5 ± 0.66∗ 21.7 ± 0.83∗,† 21.6 ± 1.13∗
Corneal nerve fiber length (CNFL) (mm/mm2) 15.5 ± 0.53 9.5 ± 0.16∗ 12.3 ± 0.31∗ 11.7 ± 0.30∗ 11.0 ± 0.38∗,† 11.3 ± 0.49∗
Corneal nerve branch density (CNBD) (no/mm2) 14.5 ± 1.2 9.6 ± 0.26∗ 9.5 ± 0.39‡ 10.0 ± 0.51‡ 9.3 ± 0.54‡ 9.1 ± 0.67§
Tortuosity grade (TG) 1.98 ± 0.06 2.49 ± 0.03∗ 2.47 ± 0.05∗ 2.51 ± 0.05∗ 2.47 ± 0.05∗ 2.54 ± 0.13∗
Beading frequency (BF) (number/0.1mm) 23.7 ± 0.29 20.4 ± 0.16∗ 20.1 ± 0.27∗ 20.9 ± 0.32∗ 20.3 ± 0.27∗ 19.6 ± 0.36∗
Bead size (BS) (𝜇m2) 7.94 ± 0.07 9.84 ± 0.05∗ 9.65 ± 0.09∗ 9.82 ± 0.08∗ 9.95 ± 0.09∗ 10.3 ± 0.17∗,†
Data are expressed as mean ± standard error of the mean (SEM) in control subjects, type 2 diabetic patients, and their subgroups stratified by the Neuropathy
Disability Score (NDS). ∗𝑝 < 0.001 compared with control subjects, †𝑝 < 0.05 compared with patients without neuropathy, ‡𝑝 < 0.01 compared with control
subjects, and §𝑝 < 0.05 compared with control subjects.
for the total patient group and the moderate neuropathy
subgroup than for controls. The HbA1c levels in the total
patient group and all diabetic subgroups were higher than
those in controls, while no difference was found between
diabetic subgroups. The LDL-cholesterol level in the total
patient group and a mild neuropathy subgroup was elevated
compared with that in controls. Statins were prescribed more
frequently for the total diabetic patients than for the controls.
The HDL-cholesterol level in the total patient group and
patients without neuropathy and with moderate neuropathy
was lower than that in controls. The triglycerides level in the
total patient group and subgroups with mild or moderate
neuropathy was increased compared with that in controls.
The ACR in the whole patient group and all diabetic sub-
groups was significantly higher than controls.There were sig-
nificant differences in the mean NDS between all subgroups
of diabetic patients stratified by NDS.
3.2. Neurological Examinations. Except for the MCV of the
median nerve, there existed no difference in the neurophys-
iological tests between controls and the subgroup without
neuropathy. The MCV, amplitude, and distal latency period
of the median nerve and the SCV and amplitude of ulnar and
sural nerve deteriorated relative to the severity of neuropathy
(Table 1). VPT increased relative to the severity of neuropathy.
CVR-R and temperature PTs in the moderate neuropathy
subgroup were impaired compared with those in controls or
patients without neuropathy (Table 1).
3.3. Corneal Nerves Morphological Parameters in Control
Subjects and Type 2 Diabetic Patients. In the cohort of
patients without neuropathy, the CNFD, CNFL, CNBD, and
BF were markedly reduced, and TG and BS were increased
compared with controls. The further mild deterioration of
CNFD and CNFL was found in the moderate neuropathy
subgroup andBS in patientswith severe neuropathy (Table 2).
BS in patients without neuropathy expanded compared with
that of controls and further expansion was found only in
patients with severe neuropathy (Figure 1).
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Figure 1: Comparison of the bead sizes of the corneal nerve fibers
between control subjects, total type 2 diabetic patients, and diabetic
subgroups stratified by the severity of neuropathy. Data are themean
± SEM. ∗𝑝 < 0.001 compared with control subjects and †𝑝 < 0.05
compared with patients without neuropathy.
Figure 2 illustrated the representative beads in original
CCM images (a), when the images were simply magnified 5
times by Photoshop (b), and when the images were enlarged
5 times with smoothing by the S-Spline Max algorithm (c)
in a control subject (1), a patient without diabetic neuropathy
(2), a patient withmild diabetic neuropathy (3), a patient with
moderate diabetic neuropathy (4), or a patient with severe
diabetic neuropathy (5). The images that were simply mag-
nified by Photoshop were not suitable to determine the pixel
numbers accurately. In comparison, the images processed by
the S-Spline Max algorithm were clearly demarcated, and the
pixel numbers were easily determined. Compared with the
BS of controls, those in diabetic patients appeared to expand.
The intrarater variability (averaged CV) in the measurement
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Figure 2:The representative beads in the original CCM images (a), images simply magnified 5 times by Photoshop (b), and images enlarged
5 times with smoothing by the S-Spline Max algorithm (c) in a control subject (1, male, 56 years, NDS: 0), patient without neuropathy (2,
male, 52 years, NDS: 1), patient with mild neuropathy (3, male, 54 years, NDS: 5), patient with moderate neuropathy (4, male, 56 years, NDS:
7), and patient with severe neuropathy (5, male, 57 years, NDS: 9).
Table 3: Differentiating efficacy of corneal nerve fiber parameters as AUC and 𝑝 values with CCM cut-off with sensitivity and specificity
between control subjects and type 2 diabetic patients without neuropathy or between type 2 diabetic patients with or without neuropathy.
Variable
Between control subjects and type 2 diabetic
patients without neuropathy
Between type 2 diabetic patients without or
with neuropathy
AUC 𝑝 value Cut-off Sensitivity Specificity AUC 𝑝 value Cut-off Sensitivity Specificity
CNFD 0.847 <0.0001 28.1/mm2 0.79 0.78 0.610 0.020 23.1/mm2 0.66 0.54
CNFL 0.830 <0.0001 13.4mm/mm2 0.79 0.68 0.585 0.071 11.6mm/mm2 0.63 0.55
BF 0.883 <0.0001 22.1/0.1mm 0.92 0.83 0.538 0.427 20.5/0.1mm 0.48 0.66
BS 0.997 <0.0001 8.47 𝜇m2 0.99 0.96 0.602 0.031 9.76 𝜇m2 0.65 0.53
BF, beading frequency; BS, bead size; CNFD, corneal nerve fiber density; CNFL, corneal nerve fiber length.
of the pixel numbers of bead in 10 control subjects was 12.7 ±
2.6%.
According to the ROC curves for the four CCM parame-
ters between controls and patients without neuropathy (NDS
< 3) (Figure 3 and Table 3), AUC was 0.847 for CNFD,
0.830 for CNFL, 0.883 for BF, and 0.997 for BS. Because the
AUC, sensitivity, and specificity of BS are the best among
parameters of CCM, it is considered that BS is the most
reliable marker of CNF alteration in type 2 diabetes before
developing neuropathy (Table 3). On the other hand, AUC
between patients without neuropathy (NDS < 3) and with
neuropathy (NDS > 3) did not seem to be useful in detecting
the presence of neuropathy: AUC was 0.610 for CNFD, 0.585
for CNFL, 0.538 for BF, and 0.602 for BS (Table 3).
3.4. Correlations between CCM Parameters and Clinical Fac-
tors or Neurophysiological Tests. There was significant corre-
lation betweenHbA1c and all CNF parameters except TG and
BF. NDS was associated with CNFD and CNFL inversely and
with BS positively (Table 4). The BS had the robust inverse
association with MCV and the positive association with the
distal latency period of themediannerve and inversely related
with the SCV of the ulnar and sural nerve. On the other hand,
CNFD and CNFL had the modest association with the NCV
as well as the amplitudes of the peripheral nerves. The weak
but significant relationships between the CNFD, CNFL, and
CNBD and CVR-R or cold PT were found, while BS had the
positive relationship with a VPT (Table 4).
4. Discussion
Diabetic neuropathy is a major complication of diabetes and
leads to significant morbidity and mortality [16].The chronic
hyperglycemia-induced changes in mitochondrial structure,
function, and dynamics may lead to the development of
diabetic neuropathy [2, 3, 17]. The increase in the number
of small mitochondria due to excessive fission in the dorsal
root fibers of db/dbmouse with diabetic neuropathy has been
reported [18]. In a study with Akita diabetic mouse with
diabetic neuropathy, sympathetic ganglia show the accumu-
lation of minute mitochondria [19]. In patients with diabetic
neuropathy the larger mitochondrial signals composed of
clustered smaller, potentially dysfunctional mitochondria or
of larger predegenerative mitochondria in IENFs due to a
disruption in axonal transport were observed [4]. In the
small fiber neuropathy patients in early stage, mitochondrial
loss was reported [11]. Since an invasive skin or nerve
biopsy is mandatory for the morphological assessment of
mitochondrial number and size, it could not be performed
as a clinical routine procedure.
6 Journal of Diabetes Research
CNFL
0.0 0.2 0.4 0.6 0.8 1.0
0.0
0.2
0.4
0.6
0.8
1.0
Re
fer
en
ce 
lin
e
CNFD
0.0 0.2 0.4 0.6 0.8 1.0
0.0
0.2
0.4
0.6
0.8
1.0
Re
fer
en
ce 
lin
e
0.0
0.2
0.4
0.6
0.8
1.0
Re
fer
en
ce 
lin
e
BF
0.0 0.2 0.4 0.6 0.8 1.0
0.0
0.2
0.4
0.6
0.8
1.0
Re
fer
en
ce 
lin
e
BS
0.0 0.2 0.4 0.6 0.8 1.0
1 − specificity
1 − specificity
1 − specificity
1 − specificity
Se
ns
iti
vi
ty
Se
ns
iti
vi
ty
Se
ns
iti
vi
ty
Se
ns
iti
vi
ty
Figure 3: Receiver operating characteristic (ROC) curve analyses for CNFD, CNFL, BF, and BS between control subjects and patients without
neuropathy (NDS < 3) (—) and between patients without neuropathy (NDS < 3) and with neuropathy (NDS > 3) (- - -).
To our knowledge, this is the largest cohort of type 2
diabetic patients that have been studied in detail for standard
clinical examinations and CCM, and the new parameters
including BS have been studied for the first time.
The CNF pathology assessed by CCM has been proposed
as a surrogate marker for a small fiber neuropathy in patients
with diabetes [6, 7], because the ROC curves for the CCM
parameters (CNFD, CNFL, and CNBD) for NDS > 3 revealed
good AUC, sensitivity, and specificity [6] and because the
CCM analysis using a conventional and novel algorithm
to reconstruct CNF images had revealed the significant
correlations between CNFD, CNFL, or CNBD and the NCV,
VPT, temperature PT, heart rate variability, or the clinical
severity of diabetic neuropathy [20]. The ROC analysis of
CCM parameters in the present study revealed that the AUC,
sensitivity, and specificity of CCMmeasures in differentiating
between control subjects and patients without neuropathy
(NDS < 3) were excellent and among the parameters of CNF
morphology, BS had the best AUC, sensitivity, and specificity.
Using the thin section of a freshly isolated human cornea
the electron microscopy can identify beads in CNFs as
a composite of the accumulated mitochondria, glycogen
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Table 4: Relationship between the various measures of corneal nerve fibers and clinical and neurophysiological parameters in patients with
type 2 diabetes.
CNFD CNFL CNBD TG BF Bead size
𝛽 𝑝 𝛽 𝑝 𝛽 𝑝 𝛽 𝑝 𝛽 𝑝 𝛽 𝑝
Gender −0.056 0.482 −0.054 0.498 0.093 0.240 −0.040 0.617 −0.083 0.295 0.034 0.669
Age −0.012 0.882 −0.060 0.450 −0.066 0.405 0.004 0.959 −0.026 0.744 0.057 0.475
Duration of DM −0.094 0.236 −0.083 0.291 −0.071 0.372 0.036 0.645 −0.025 0.750 −0.040 0.617
SBP −0.107 0.176 −0.105 0.183 0.011 0.886 −0.107 0.174 −0.010 0.902 −0.032 0.685
DBP −0.132 0.093 −0.113 0.150 0.015 0.848 −0.139 0.079 −0.004 0.961 0.017 0.830
HbA1c −0.200 0.011 −0.213 0.007 −0.168 0.032 0.003 0.973 −0.080 0.313 0.352 <0.0001
LDL-C 0.028 0.724 0.011 0.891 −0.007 0.925 0.075 0.343 −0.116 0.141 −0.006 0.937
HDL-C −0.052 0.509 −0.105 0.182 −0.066 0.403 0.032 0.683 0.027 0.731 −0.043 0.586
Triglycerides −0.038 0.633 −0.060 0.451 −0.077 0.330 0.034 0.670 −0.015 0.848 0.002 0.984
NDS −0.255 0.001 −0.208 0.008 −0.019 0.815 0.034 0.665 −0.012 0.883 0.203 0.010
MCV of MN 0.199 0.011 0.193 0.014 0.054 0.494 0.063 0.426 0.050 0.526 −0.358 <0.0001
Amplitude of MN 0.208 0.008 0.172 0.028 −0.009 0.914 −0.083 0.292 −0.028 0.722 0.091 0.248
Distal latency of MN −0.090 0.256 −0.090 0.256 −0.018 0.819 −0.083 0.295 0.065 0.413 0.294 <0.0001
SCV of UN 0.200 0.011 0.225 0.004 0.138 0.079 0.070 0.379 0.037 0.644 −0.273 <0.0001
Amplitude of UN 0.195 0.013 0.215 0.006 0.040 0.616 −0.031 0.699 0.053 0.504 0.083 0.294
SCV of SN 0.201 0.010 0.223 0.004 0.107 0.175 0.105 0.183 0.031 0.698 −0.237 0.002
Amplitude of SN 0.224 0.004 0.232 0.003 0.076 0.339 −0.064 0.417 0.098 0.215 0.004 0.963
Vibration PT −0.019 0.812 0.029 0.803 0.016 0.837 0.097 0.220 −0.046 0.562 0.199 0.011
CVR-R 0.161 0.040 0.210 0.007 0.170 0.030 −0.026 0.744 0.009 0.909 −0.098 0.216
Warm PT 0.021 0.790 −0.002 0.985 −0.073 0.358 −0.149 0.058 −0.025 0.753 0.051 0.523
Cold PT −0.142 0.071 −0.157 0.046 −0.015 0.853 −0.030 0.706 −0.028 0.727 0.025 0.754
BF, beading frequency; CNBD, corneal nerve branch density; CNFD, corneal nerve fiber density; CNFL, corneal nerve fiber length; CV, coefficient of variation;
DBP, diastolic blood pressure; DM, diabetes mellitus; HDL-C, high density lipoprotein-cholesterol; LDL-C, low density lipoprotein-cholesterol; MCV, motor
conduction velocity; MN, median nerve; NDS, Neuropathy Disability Score; PT, perception threshold; SBP, systolic blood pressure; SCV, sensory conduction
velocity; SN, sural nerve; TG, tortuosity grade; UN, ulnar nerve.
particles, and vesicles [8, 21] playing some role in controlling
CNF functions [21] with similar ultrastructure to nociceptor
terminals. The present study revealed that BF decreased and
BS expanded in patients with diabetes compared with control
subjects. In the present study BS inversely associated with
CNFD (𝑟 = −0.269, 𝑝 < 0.001), CNFL (𝑟 = −0.212, 𝑝 =
0.003), and CNBD (𝑟 = −0.229, 𝑝 = 0.001), and BF had
positive relationship with CNFD (𝑟 = 0.252, 𝑝 < 0.001),
CNFL (𝑟 = 0.205, 𝑝 = 0.005), and CNBD (𝑟 = 0.184, 𝑝 =
0.011). Therefore, altered beading structures may have rela-
tionship with the loss ofmain nerve fibers as well as branches.
Although the increased irregularity in the periodicity of CNF
beading has been reported in streptozotocin- (STZ-) diabetic
rat [22], alteration in the BS and in composition of bead
remained to be clarified. The axonal trafficking of mitochon-
dria is controlled by cytoskeletons, motor proteins, and ATP
fuel supply [23]. In STZ-diabetic rats, axonal neurofilaments
in peripheral nerve were deleted [24], and sciatic level of
kinesin 5B motor protein which is involved in the axonal
transport of mitochondria is changed [25]. These results
suggested that changes in the distribution of mitochondria
in CNFs might occur resulting in altered number and size
of beads. However, we could not determine the exact mito-
chondrial area in bead using mitochondria marker, because
the present study was an in vivo human study using CCM.
Therefore, the contribution of mitochondrial number and
size to the BS remained to be determined. In patients with
diabetic neuropathy [26] and the spontaneously diabetic BB-
Wistar-rat [27], mitochondrial accumulation of glycogen par-
ticles was observed. In experimental diabetic animals, the loss
of vesicles in presynapse [28] and autonomic nerve endings
[29] was reported. Therefore, the alterations in components
of bead other than mitochondria might influence the density
and size of bead.
The present research found the significant relationships
between parameters of main CNF and branch and the NCV
and amplitudes of the peripheral nerves, heart rate variability,
and a cold PT. Although we and others previously reported
the preliminary findings of lower BF of CNFs in diabetic
patients [30–32], the relationship between the BS and neu-
rophysiological tests had never been investigated. The beads
can be clearly demonstrated along CNFs by CCM. However,
the individual bead in the original CCM image is too small for
assessing its area.The enlarging and smoothing of the original
CCM image by S-Spline Max algorithm enable us to deter-
mine the size of an individual bead in CNFs in spite of the
uncertain accuracy and exactness of this method.
Based on the current results, CCM can detect CNF
alteration in patients without clinical evidence of neuropathy
compared with those of the controls. According to ROC
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analysis BS had the largest AUC with the best sensitiv-
ity and specificity compared with CNFD, CNFL, and BF.
These results indicated that the diabetes-induced expansion
of BS and changes in other morphological parameters of
CCM might have predictive value for the dysfunctions of
the peripheral nerves. The expansion of beads occurred in
patients without the neuropathy, getting larger in patients
with severe neuropathy. The BS had good negative relation-
ship withMCV and SCVof the peripheral nerves and directly
associated with a distal latency period of themedian nerve. In
the present study the BS correlated strongly to HbA1c levels.
In myelinated murine axon, the oxidative stress alters the
external morphology and reduces the transport of mitochon-
dria at the nodes of Ranvier. These mitochondrial changes
expand from the node of Ranvier bidirectionally [33]. In STZ-
diabetic mice, there is a significant increase in synaptic delay
compared with control mice, and the accumulation of degen-
erated mitochondria of presynaptic axon of the neuromuscu-
lar junction was observed [34]. However, because there has
been no report investigating the morphological changes in
mitochondria of CNFs in patients with diabetes, we could not
assume that the bead in the CNFs is a surrogate marker of the
size ofmitochondrial area in the peripheral nerves in diabetic
patients.
We acknowledge limitations to the present study, which
may affect the interpretation of the results. First, although we
measured the BS of CNF in patients with type 2 diabetes, we
did not determine whether the number of mitochondria in
an expanded bead in CNFs increased or not. Furthermore,
alteration in other components of bead could influence BS.
Second, we assessed BS after enlarging and smoothing of
original bead. However, the accuracy and preciseness of this
method were not established. The future improvement in a
resolution of CCM apparatus will make it possible to assess
the BS directly using an original CCM image. Lastly, the
potential bias determining BF and BS by human errors could
not be ruled out. The automatic analyzing system for bead-
ing as already developed for other corneal morphological
parameters of CNFs [35] would eliminate this type of errors.
5. Conclusions
In conclusion, the expansion of beads of the CNFs in patients
with type 2 diabetes occurred before the development of neu-
ropathy and was related to the slow NCV and the prolonged
distal latency period of the peripheral nerves. The BS in the
CNFs has a predictive value for developing the slow NCV of
the peripheral nerves in patients with type 2 diabetes. How-
ever, elucidating the mechanisms of the expansion of bead in
CNFs was beyond the scope of the present study.
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